linjc16/ctgov huggingface dataset:
Impact of Ostracism on Prospective Memory in ADHD Children With or Without Emotional Dysregulation

Study Overview
=================
Brief Summary
-----------------
Assess the effect of exposure to a situation of social exclusion or ostracism on the prospective memory of children with ADHD

Official Title
-----------------
Impact of Ostracism on Prospective Memory in ADHD Children With or Without Emotional Dysregulation/ Impact de l'Ostracisme Sur la mémoire Prospective Chez Des Enfants Atteint de TDA/H Avec ou Sans dysrégulation émotionnelle.

Conditions
-----------------
ADHD

Intervention / Treatment
-----------------
* Behavioral: Cyberball


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Child with attention deficit disorder with or without hyperactivity (ADHD) according to the following criteria: score greater than 27 on the ADHD-RS scale or score greater than 65 on the Conners scale, and after clinical staff discussion Social security non opposition of parents and children to the study Exclusion Criteria: Subject presenting elements in favor of a depressive disorder according to a clinical evaluation and on an evaluation by the CBCL scale Minor and/or parents who do not understand French Person under legal protection, adult guardianship or curatorship.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: one arm study<br>Memory test performed before and after cyberball task | Behavioral: Cyberball<br>* Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference between prospective memory tests performed before and after cyberball task | Promacy test is a Memory test performed before and after Cyberball task | At inlcusion |
TcMS to Treat Ventricular Tachycardia

Study Overview
=================
Brief Summary
-----------------
Open label study of transcutaneous magnetic stimulation targeting the stellate ganglion in patients with ventricular tachycardia

Official Title
-----------------
Transcutaneous Magnetic Stimulation of the Stellate Ganglion to Treat Ventricular Tachycardia

Conditions
-----------------
Ventricular Tachycardia

Intervention / Treatment
-----------------
* Device: TcMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18years Documented ventricular tachycardia within the preceding 72 hours Exclusion Criteria: Pregnancy Implanted ventricular assist device Metal implanted in heard or neck (except the mouth) Implanted medication pumps Cochlear implant Implanted brain stimulator Ocular implant History of malignancy in the region of stimulation (neck)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Transcutaneous magnetic stimulation<br>Transcutaneous magnetic stimulation targeting the stellate ganglion | Device: TcMS<br>* Transcutaneous magnetic stimulation targeting the stellate ganglion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ventricular Tachycardia | Burden (number of episodes) of ventricular tachycardia | 0-72 hours after enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Non sustained ventricular tachycardia | Burden (number of episodes) of ventricular tachycardia | 0-72 hours after enrollment | 
| Discomfort | Discomfort experienced during stimulation (on scale of 0-10) reported by patient | Assessed immediately following stimulation |
A SBT-based Protocol-directed Program in Difficult-to-Wean Patients

Study Overview
=================
Brief Summary
-----------------
Weaning patients from a ventilator is one of the most challenging processes in an intensive care unit. The investigators aimed to determine whether spontaneous breathing trial (SBT)-based protocol-directed weaning combined with the high-flow nasal cannula (HFNC) could be superior to routine SBT-based weaning in reducing the duration of mechanical ventilation (MV) in difficult-to-wean patients.

Official Title
-----------------
A Spontaneous Breathing Trial-based Protocol-directed Program in Difficult-to-Wean Patients

Conditions
-----------------
Respiration, Artificial

Intervention / Treatment
-----------------
* Procedure: a weaning protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 16 years old MV for more than 48 hours intubated or tracheostomized Exclusion Criteria: pregnancy irreversible respiratory failure caused by neurodegenerative disorders, such as Alzheimer disease, motor neuron disease, or multiple system atrophy pre-existing decision to limit life support waiving of MV during treatment terminal stage of severe illness

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: weaning protocol group<br>spontaneous breathing trial (SBT)-based protocol-directed weaning combined with the high-flow nasal cannula group | Procedure: a weaning protocol<br>* a weaning protocol that is combined spontaneous breathing trial (SBT) with the high-flow nasal cannula (HFNC)<br>|
| No Intervention: routine SBT weaning group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mechanical ventilation days | the duration of mechanical ventilation | 60 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| re-intubated within 24 hours | re-intubated within 24 hours | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Protocol-directed weaning, Mechanical ventilation, High-flow nasal cannula, Spontaneous breathing trial
Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Study Overview
=================
Brief Summary
-----------------
Determination of response rate Assessment of toxicity and determination of time to progression

Detailed Description
-----------------
Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy

Official Title
-----------------
Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy

Conditions
-----------------
Recurrent Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: Bendamustin/Ribomustin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with histological proven, curative non treatable small lung cell carcinoma Recurrence >8 weeks, > 1 year after 1st line treatment with platin- and etoposide polychemotherapy, without brain metastases Exclusion Criteria: Brain metastases WHO-PS 3 - 4

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Bendamustin/Ribomustin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of response rate ( CR + PR) after cytostatic therapy with Bendamustin 120mg/m2, day 1+2, repeat d 22 |  |  | 
| (primary goal) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of toxicity, determination of time to progression, for median survival and one-year survival rate,investigation of life quality (secondary goal) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recurrent SCLC
Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients

Study Overview
=================
Brief Summary
-----------------
xerostomia develops in all patients with head and neck cancer following radiotherapy. it consists one of the main side effects which affects quality of life. currently, there is no standard of care for treating this condition. parasympathomimetic drugs may help but carry significant side effects. hypnosis may affect autonomic function such as salivation, in healthy people.in this study we will explore the efficacy of hypnosis in improving salivation, in the patient population.

Detailed Description
-----------------
10 head and neck cancer patients with xerostomia following radiotherapy will be assessed for severity of xerostomia using questionnares and quantitative salivation tests. patients responsive to citric acid will receive a hypnotic session with specific suggestion for salivation. saliva volume will be assessed pre and post hypnosis. patients will receive a CD with recorded hypnotic session to use freely at home. xerostomia will be assessed using a questionnare one week following hypnosis.

Official Title
-----------------
Phase 2 Study of Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients

Conditions
-----------------
Xerostomia

Intervention / Treatment
-----------------
* Behavioral: hypnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: radiotherapy for head and neck cancer xerostomia Exclusion Criteria: psychiatric illness (present or past)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: hypnosis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| salivaa volume |  |  | 
| quality of life related to salivation |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
xerostomia, hypnosis, dry mouth, radiotherapy, head and neck cancer
Severe Complications Triplicate the Costs of Major Surgical Procedures

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to prospectively assess the impact of surgical quality on the overall cost of major surgical procedures using the incidence and severity of complications as surrogate markers of quality.

Detailed Description
-----------------
To prospectively assess the impact of surgical quality on the overall cost of major surgical procedures using the incidence and severity of complications as surrogate markers of quality

Official Title
-----------------
Surgical Complications Dramatically Influence Overall Cost of Major Surgical Procedures

Conditions
-----------------
Major Surgical Procedures

Intervention / Treatment
-----------------
* Other: No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) Exclusion Criteria: Missing data of in-hospital costs Mortality

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Costs<br>Patients collected consecutively for undergoing major surgical procedures(liver, bile duct, pancreas, small bowel, colo-rectal, gastric bypass resections). | Other: No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel<br>* No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical outcome (complications) In-hospital Costs |  | inhospital; peri-operative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Clinical outcome (complications), in-hospital costs, The influence and impact of postoperative complications on in-hospital costs
POGO® Automatic Blood Glucose Monitoring System Clinical Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the POGO® system delivers accurate blood glucose readings in the hands of the lay user and assess the POGO® system accuracy when used by trained health care professionals.

Detailed Description
-----------------
Subjects will review labeling materials and self-test using the POGO® system. An HCP-assisted test also will be performed; both tests will be compared to a fingerstick capillary sample run on a YSI reference glucose analyzer. Subjects will complete questionnaires on labeling comprehension and POGO® usability.

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: POGO® BGMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be diagnosed with diabetes Be 18 years of age or older Be able to read, write, and understand English fluently Be able and willing to give written informed consent and have provided signed, written consent Exclusion Criteria: Any condition which in the opinion of the Investigator may place the subject or site personnel at excessive risk A physical condition or limitation that prevents the subject from reading the labeling and using a BGMS on their own Previous experience with the POGO® BGMS Formal experience with clinical (medical) laboratory equipment or formal training in a relevant medical field

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PWD testing POGO® BGMS<br>All enrolled persons with diabetes | Device: POGO® BGMS<br>* SMBG<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy Validation of the POGO® BGMS: Minimum outcome of 95% of results within 20% of reference measurement. | Lay-user accuracy | Blood glucose measured at time of single visit for each subject, endpoint evaluated at completion of study (approximately four months after initiation.) | 
| Accuracy Verification of the POGO® BGMS: Minimum outcome of 95% of results within 20% of reference measurement. | HCP accuracy | Blood glucose measured at time of single visit for each subject, endpoint evaluated at completion of study (approximately four months after initiation.) |
Use of Surface Electromyography Biofeedback to Improve Reaching in Children With Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
A newly-developed device for biofeedback of surface EMG will be used to either increase or decrease activity in the muscles of children with poor reaching due to cerebral palsy.

Detailed Description
-----------------
Children ages newborn to 21 with a diagnosis of arm weakness, hypertonia, or hyperkinesia due to cerebral palsy will be recruited. A muscle that is either over-active or under-active will be selected for each child. The child will be provided with the device to wear for 1 month in order to call attention to the identified muscle. At the beginning and end of the month, reaching will be assessed using three-dimensional kinematic motion capture. The outcome measure will be the speed and curvature of reaching to a target in front of the child.

Conditions
-----------------
Weakness, Cerebral Palsy, Hypertonia

Intervention / Treatment
-----------------
* Device: surface EMG biofeedback


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: weakness, hypertonia, or hyperkinetic disorder affecting one or both arms reduced speed or quality of reaching Exclusion Criteria: any condition that would increase the risk of participation

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: surface EMG biofeedback|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
movement disorders, childhood
Lived Experience, Representations and Psychic Processes in Patients Awaiting Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
The kidney transplant remains the privileged treatment of the terminal renal insufficiency. This care is complex for the patient both on a medical surgical plan and by the psychic reorganizations. Among the temporary contraindications of transplantation, us retrouvonsdes psychological reasons. The research work consists in highlighting the psychic mechanisms of the subjects awaiting kidney transplant.

Official Title
-----------------
 Expérience Vécue, Représentations et Processus Psychiques Chez Les Sujets en Attente de Transplantation Rénale 

Conditions
-----------------
Kidney Tranplant

Intervention / Treatment
-----------------
* Behavioral: Psychic processes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old stade 4 or 5 renal insufficiency Registered on waiting list for a first kidney transplant Exclusion Criteria: in ward Unsigned consent Already transplanted

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Psychic processes<br>Quantitative and qualitative approche of the psychic process for patients awaiting kidney transplant | Behavioral: Psychic processes<br>* Quantitative and qualitative aprroche of the psychic process<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of anxiety | STAI-Y questionnaire with 20 items used to measure anxiety degree | 6 months | 
| Measure of psychic representations around transplant | ETA test: this test consists of an interview then the psychic projection through the drawing of 3 trees imagined by the patient and talking about him. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
kidney transplant, psychic process
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

Study Overview
=================
Brief Summary
-----------------
To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium

Official Title
-----------------
A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium

Conditions
-----------------
Urologic Neoplasms, Carcinoma, Transitional Cell

Intervention / Treatment
-----------------
* Drug: Gemcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically and/or cytologically confirmed TCC Received 1st line chemotherapy for locally advanced or metastatic TCC with CDDP regimen To have at least one measurable region PS: 0-2 To have adequate organ function (bone marrow, liver and renal function) Exclusion Criteria: To have Interstitial pneumonia or pulmonary fibrosis Within 4 weeks after the latest chemotherapy or radiotherapy To have brain metastasis with symptom To have severe complication (cardiac infarction, infection, drug hyper sensitivity or diabetes)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gemcitabine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival |  |  | 
| Overall survival |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transitional cell carcinoma of urothelium